Skip to content

Advertisement

  • Research
  • Open Access

Risk of sepsis in patients with primary aldosteronism

  • 1, 2, 8,
  • 3,
  • 4,
  • 5,
  • 2,
  • 2,
  • 6,
  • 2,
  • 2, 7Email author,
  • 2, 7 and
  • 7
Critical Care201822:313

https://doi.org/10.1186/s13054-018-2239-y

  • Received: 22 March 2018
  • Accepted: 15 October 2018
  • Published:

Abstract

Background

The interaction between hyperaldosteronism and immune dysfunction has been reported and glucocorticoid co-secretion is frequently found in primary aldosteronism (PA). The aforementioned conditions raise the possibility of the infection risk; however, clinical episodes of sepsis have not been reported in PA.

Methods

Using Taiwan’s National Health Insurance Research Database between 1997 and 2009, we identified PA and aldosterone-producing adenoma (APA) matched with essential hypertension (EH) at a 1:1 ratio by propensity scores. The incidences of sepsis and mortality after the index date were evaluated, and the risk factors of outcomes were identified using adjusted Cox proportional hazards models and taking mortality as a competing risk.

Results

We enrolled 2448 patients with PA (male, 46.08%; mean age, 48.4 years). There were 875 patients who could be ascertained as APA. Taking mortality as the competing risk, APA patients had a lower incidence of sepsis than their matched EH patients (hazard ratio (HR) 0.29; P < 0.001) after target treatments. Patients receiving adrenalectomy showed a benefit of decreasing the risk of sepsis (PA vs EH, HR 0.14, P = 0.001; APA vs EH, HR 0.16, P = 0.003), but mineralocorticoid receptor antagonist treatment may differ. Compared with matched control cohorts, patients with APA had a lower risk of all-cause mortality (PA, adjusted HR 0.84, P = 0.050; APA, adjusted HR 0.31, P < 0.001) after target treatments.

Conclusions

Our study demonstrated that patients with PA/APA who underwent adrenalectomy could attenuate the risk of sepsis compared with their matched EH patients. We further found that APA patients with target treatments could decrease all-cause mortality compared with EH patients.

Keywords

  • Primary aldosteronism
  • Hypertension
  • Sepsis
  • Oxidative stress
  • Chronic inflammation
  • Glucocorticoid
  • Taiwan Primary Aldosteronism Investigation

Background

Primary aldosteronism (PA), characterized by an inappropriate production of aldosterone, is the most common form of secondary hypertension [1, 2]. Current studies have demonstrated that aldosterone oversecretion is not only related to fluid overload and hypokalemia but also resulted in cardiovascular and renal damage [3, 4].

Hyperaldosteronism is associated with proinflammatory immune dysregulation, such as the release of proinflammatory cytokines [5] and generating oxidative stress [6]. Systemic aldosterone infusion leads to oxidative stress and inflammation in the rat myocardium [7]. In human leucocytes, mineralocorticoid receptor (MR) expression has been reported in the CD34+ hematopoietic progenitor, and in peripheral blood T and B lymphocytes, monocytes, and neutrophils turning them sensitive to aldosterone stimulation [8]. On the other hand, recent studies [9, 10] have reported that glucocorticoid oversecretion was found in PA. In Cushing’s syndrome, glucocorticoid oversecretion can affect both the cellular and humoral components of the innate immune system [11]. The aforementioned condition raised the possibility of immune dysregulation in PA and it is reasonable to hypothesize that PA was associated with a higher risk of severe infection than other disease with immune dysregulation status [11]. However, there were few reports about the outcome of sepsis in PA patients. In addition, it is still unclear whether adrenalectomy for aldosteronism also leads to relevant hypocortisolism for a variable stress condition, especially during sepsis.

To study the effect of aldosterone on immune dysfunction, it is important to evaluate the risk of sepsis and septic shock among PA patients and the benefit of targeting treatments to PA patients. Therefore, we took advantage of the National Health Insurance registration database to conduct a large longitudinal population study about the correlation between sepsis and PA.

Methods

Data source

Our study used a longitudinal database created by the National Health Research Institutes (NHRI) through extracting original Taiwan National Health Insurance (TNHI) data (23.12 million insured population in 2009) for all patients who had ever had a PA diagnosis from 1997 to 2009. This database enabled us to investigate each patient from the day of PA diagnosis until the day of death, NHI disenrollment, or the end of 2010, whatever occurred first. Disenrollment from Taiwan’s NHI is rarely observed because the NHI is universal and compulsory for Taiwan’s citizens and foreigners with residence permits. For a person who should enroll in the NHI, disenrollment only occurs when the person is going to be overseas for at least 6 months or has been missing for at least 6 months. The NHI covers a broad spectrum of health services. As indicated by the Taiwan National Health Interview Survey data, the NHI offers healthcare in almost all outpatient visits and hospital stays for Taiwan’s citizens. Thus, our database includes nearly all medical records for each patient.

We used a validated algorithm to identify PA patients, and enrolled patients aged ≥18 years at the time of first medical record of PA (9th edition of International Classification of Diseases, ICD-9 code 255.1). The administrative data on diagnosis of and identifying PA patients has been well validated [12]. Figure 1 depicts the algorithm for selecting study patients. We only enrolled patients who used mineralocorticoid receptor antagonist (MRA) (belonging to the Anatomical Therapeutic Chemical (ATC) classification system, class C03D), because this additional condition assured high values for both sensitivity and positive predictive value [12, 13]. Patients with aldosterone-producing adenoma (APA) were enrolled from patients with PA who had undergone adrenalectomy or received a diagnosis of adrenal adenoma [1214]. Each PA and APA patient was then matched with one patient with essential hypertension (EH) (without PA diagnosis and had used antihypertensive drugs) according to age, sex, and propensity score. We further separated PA and APA patients into two groups according to the target treatments, as those who received adrenalectomy or only MRA.
Fig. 1
Fig. 1

Flowchart of participants. *Patients who did not use MRA during the year before or 2 years after the first PA coding. APA aldosterone-producing adenoma, EH essential hypertension, ICD International Classification of Diseases, MRA mineralocorticoid receptor antagonist, PA primary aldosteronism

Baseline characteristics

Concomitant medication data associated with blood pressure and outcome were recorded. The inotropic agents used during sepsis were also identified. The NHRI claims data regarding adrenalectomy and medications are reliable because they were copied on the basis of the NHI procedure and drug codes that were tied to the NHRI reimbursement system with auditing. The indication and guideline for hypertensive management in Taiwan have been proposed and revised by the Taiwan Hypertension Society [15]. Briefly, a diagnostic algorithm was proposed, emphasizing the ESH/ESH joint hypertension guidelines suggestion to loosen BP targets to < 140/90 mmHg for all patients [15].

Outcomes

The main study outcome was incident sepsis after the index date. The identification of patients with sepsis was similar to that used by Lai et al. [16], who selected all acute-care hospitalizations with ICD-9-CM codes for both bacterial or fungal infection processes and a diagnosis of acute organ dysfunction. We used codes for acute organ dysfunction, as modified by Shen et al. [17] (Additional file 1). Sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) as systemic inflammatory syndrome in response to infection, associated with acute organ dysfunction [18]. Septic shock was defined as sepsis with inotropic agents used during index episodes (Additional file 2). For patients with more than one hospital admission for sepsis during the study period, we only include the first episode of sepsis. We also recorded the risk of the all-cause mortality as the secondary outcome indicators. If a patient had not encountered any event at the time of NHI disenrollment or the end of 2010, we categorized this patient as a censored observation in our survival analysis.

To develop and test a standardized method for assessing the quality (completeness and accuracy) of clinical databases, a directory of clinical databases (DocDat) has been established [19]. In our database, most criteria had achieved Level 3 and Level 4, which indicated that our database had good quality and strength.

Statistical analysis

Continuous variables were expressed as a mean ± standard deviation and categorical variables were expressed as a percentage. We matched PA /APA patients to their EH patients using a greedy matching algorithm with a caliper width of 0.2 standard differences (SDs) of the log odds of the estimated propensity score. The sampling ratios between patients of PA to EH and of APA to EH were 1:1 [20, 21]. Statistical significance was defined as two-sided P < 0.05.

In various subsequent multivariable models for analyzing outcomes, we also took into account the propensity score for the PA diagnosis in order to minimize residual confounding effects in the matching process (Additional file 3). Additional adjustment in these models included control for direct effects from age, gender, concomitant medications (except inotropic agents), and comorbidities as presented in Table 1. Cox regression models with a conditional approach and stratification were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of sepsis, mortality, and septic shock in each group. In further parametric modeling with regard to factors associated with outcome, we adopted three modeling methods: simple Cox regression, multivariable Cox regression, and competing risk regression. Because of the high mortality rate and sepsis rate in patients of old age and male patients, competing risk regression using the Fine and Gray model by considering the subdistribution hazard was also performed [22].
Table 1

Comparison of characteristics between PA and EH patients, for the whole PA cohort and for the APA subgroup only

Category

Matched EH/PA

Matched EH/APA

EH

(n = 2448)

PA

(n = 2448)

p

EH

(n = 875)

APA

(n = 875)

p

Propensity score

−3.92 ± 1.72

− 3.92 ± 1.72

0.995

−0.95 ± 0.38

−0.95 ± 0.38

0.993

Male gender

1146 (46.81%)

1128 (46.08%)

0.626

375 (42.86%)

377 (43.09%)

0.961

Age

48.40 ± 13.52

48.40 ± 13.52

0.999

46.62 ± 12.77

46.31 ± 10.55

0.829

Comorbidity

 Congestive heart failure

11 (0.45%)

8 (0.33%)

0.647

2 (0.23%)

3 (0.34%)

0.999

 Cerebrovascular disease

105 (4.29%)

101 (4.13%)

0.831

29 (3.31%)

41 (4.69%)

0.179

 CKD

29 (1.18%)

43 (1.76%)

0.122

8 (0.91%)

7 (0.80%)

0.999

 COPD

91 (3.72%)

92 (3.76%)

0.999

19 (2.17%)

17 (1.94%)

0.867

 Coronary artery disease

1 (0.04%)

5 (0.20%)

0.218

N/A

N/A

N/A

 Dementia

10 (0.41%)

11 (0.45%)

0.999

1 (0.11%)

2 (0.23%)

0.999

 Diabetes mellitus

208 (8.50%)

203 (8.29%)

0.837

55 (6.29%)

66 (7.54%)

0.346

 Hemiplegia

7 (0.29%)

7 (0.29%)

0.999

1 (0.11%)

4 (0.46%)

0.374

 Liver disease

107 (4.37%)

100 (4.08%)

0.670

25 (2.86%)

32 (3.66%)

0.419

 Peptic ulcer

154 (6.29%)

138 (5.64%)

0.365

37 (4.23%)

48 (5.49%)

0.266

 Peripheral vascular disease

8 (0.33%)

7 (0.29%)

0.999

3 (0.34%)

2 (0.23%)

0.999

 Rheumatoid arthritis

15 (0.61%)

6 (0.25%)

0.078

2 (0.23%)

2 (0.23%)

0.999

 Solid tumor

43 (1.76%)

49 (2.00%)

0.599

14 (1.60%)

16 (1.83%)

0.854

 SLE

2 (0.08%)

2 (0.08%)

0.999

1 (0.11%)

1 (0.11%)

0.999

 AF

10 (0.41%)

10 (0.41%)

0.999

4 (0.46%)

2 (0.23%)

0.687

 Dyslipidemia

203 (8.29%)

194 (7.92%)

0.675

76 (8.69%)

65 (7.43%)

0.380

 Alzheimer disease

0 (0.00%)

1 (0.04%)

0.999

0 (0.00%)

1 (0.11%)

0.999

 Parkinson disease

14 (0.57%)

10 (0.41%)

0.540

4 (0.46%)

1 (0.11%)

0.374

Hypertensive drugs by categories

 Alpha-blocker

171 (6.99%)

187 (7.64%)

0.410

75 (8.57%)

78 (8.91%)

0.866

 ACEI or ARB

1014 (41.42%)

997 (40.73%)

0.642

417 (47.66%)

403 (46.06%)

0.533

 Beta-blocker

1165 (47.59%)

1157 (47.26%)

0.841

465 (53.14%)

473 (54.06%)

0.737

 Calcium-channel blocker

1556 (63.56%)

1528 (62.42%)

0.424

631 (72.11%)

626 (71.54%)

0.832

 Diuretic

1091 (44.57%)

1106 (45.18%)

0.687

416 (47.54%)

385 (44.00%)

0.150

Other concomitant medications

 Aspirin

62 (2.53%)

58 (2.37%)

0.782

20 (2.29%)

21 (2.40%)

0.999

 Clopidogrel

7 (0.29%)

8 (0.33%)

0.999

2 (0.23%)

5 (0.57%)

0.452

 Ticlopidine

10 (0.41%)

10 (0.41%)

0.999

2 (0.23%)

3 (0.34%)

0.999

 Warfarin

16 (0.65%)

10 (0.41%)

0.326

9 (1.03%)

3 (0.34%)

0.145

 PPI

79 (3.23%)

65 (2.66%)

0.271

24 (2.74%)

20 (2.29%)

0.647

 H2 blocker

190 (7.76%)

176 (7.19%)

0.480

63 (7.20%)

61 (6.97%)

0.926

 Statin

119 (4.86%)

112 (4.58%)

0.686

38 (4.34%)

36 (4.11%)

0.906

 NSAID

1136 (46.41%)

1114 (45.51%)

0.547

408 (46.63%)

393 (44.91%)

0.502

 Steroid

182 (7.43%)

186 (7.60%)

0.871

67 (7.66%)

58 (6.63%)

0.458

 SSRI

58 (2.37%)

42 (1.72%)

0.129

19 (2.17%)

15 (1.71%)

0.604

 Nitrate

4 (0.16%)

5 (0.20%)

0.999

1 (0.11%)

0 (0.00%)

0.999

Inotropic agents used during index hospitalization

 Dopamine

3 (0.12%)

3 (0.12%)

0.999

2 (0.23%)

1 (0.11%)

0.999

 Norepinephrine

17 (0.69%)

16 (0.65%)

0.999

7 (0.80%)

2 (0.23%)

0.179

 Vasopressin

9 (0.37%)

0 (0.00%)

0.004

4 (0.46%)

0 (0.00%)

0.125

 Epinephrine

39 (1.59%)

39 (1.59%)

0.999

14 (1.60%)

2 (0.23%)

0.004

Outcome

 Sepsis

87 (3.55%)

104 (4.25%)

0.238

29 (3.31%)

9 (1.03%)

0.001

 Septic shock

58 (2.37%)

57 (2.33%)

0.999

19 (2.17%)

6 (0.69%)

0.014

 Mortality

273 (11.15%)

236 (9.64%)

0.092

84 (9.60%)

28 (3.20%)

< 0.001

All data presented as number (%), except mean age, Charlson Comorbidity Index Score, and propensity score

ACEI angiotensin-converting enzyme inhibitor, AF atrial fibrillation, APA aldosterone-producing adenoma, ARB angiotensin II receptor blocker, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, EH essential hypertension, NA nonavailable, NSAID nonsteroidal antiinflammatory drug, PA primary aldosteronism, PPI proton-pump inhibitor, SLE systemic lupus erythematosus, SSRI selective serotonin reuptake inhibitor

We used R software, version 2.8.1 (Free Software Foundation, Inc., Boston, MA, USA); competing risk analysis was performed with Stata/MP version 12 (Stata Corporation, College Station, TX, USA). Two-sided P < 0.05 was considered statistically significant.

Results

Characteristics of the study population

After propensity score matching, 2448 patients with PA were matched to the 2448 patients with EH (Fig. 1). Among these 4896 patients, only 22 patients (10 in PA group and 12 in EH group) disenrolled from the NHI before the end of 2010 and remained alive at the time of NHI disenrollment. These 22 patients were treated as censored observations with regard to outcome. The propensity score, gender, age, comorbidities, and ascertained drugs were not significantly different between the two cohorts. The mean age of the PA patients was 48.4 years at the time of PA diagnosis, and the proportion of men was 46.1% (Table 1). There were 875 patients who could be ascertained as APA and were matched with 875 EH patients (Fig. 1).

Long-term risks of sepsis and mortality between PA and matched EH patients

The PA cohort had a similar sepsis rate as the EH cohort (4.25% vs 3.55%, P = 0.238) during a mean follow-up period of 4.28 years. The mortality rate in the PA and EH cohorts was similar (9.64% vs 11.15%, P = 0.092) (Table 1).

The adjusted HR for developing sepsis among the PA cohort after target treatments, relative to the EH cohort, was 1.18 (P = 0.250), taking into account the competing effects of death, corresponding to an absolute detrimental risk of 1.0 per 1000 person-years. The competing risk of mortality-adjusted HR for developing septic shock between the PA and EH cohorts was 0.96 (P = 0.850) (Table 2). The adjusted HR after target treatments for developing morality among the PA cohort, relative to the EH cohort, was 0.84 (P = 0.050) (Table 1).
Table 2

Incidence and risks for outcomes of interest between PA patients and their EH matches, for the whole PA cohort and for the APA subgroup only

Outcome

Crude

Adjusteda

Competing riskb

 

Events

Person-years

Incidence rate per 1000 person-years

Events

Person-years

Incidence rate per 1000 person-years

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

 

PA

EH

PA vs EH

Sepsis

104

13,652.95

7.6

87

13,144.31

6.6

1.15 (0.87, 1.53)

0.332

1.17 (0.88, 1.55)

0.286

1.18 (0.89, 1.57)

0.250

Septic shock

57

13,772.55

4.1

58

13,211.21

4.4

0.94 (0.65, 1.36)

0.754

0.96 (0.66, 1.38)

0.816

0.96 (0.67, 1.39)

0.850

All-cause mortality

236

13,836.93

17.1

273

13,268.23

20.6

0.83 (0.70, 0.99)

0.035

0.84 (0.71, 1.00)

0.050

N/A

N/A

 

APA

EH

APA vs EH

Sepsis

9

5550.02

1.6

29

5104.02

5.7

0.28 (0.13, 0.59)

0.001

0.28 (0.13, 0.59)

0.001

0.29 (0.14, 0.61)

< 0.001

Septic shock

6

5556.85

1.1

19

5122.85

3.7

0.28 (0.11, 0.71)

0.007

0.28 (0.11, 0.71)

0.007

0.30 (0.12, 0.75)

0.010

All-cause mortality

28

5567.03

5

84

5141.56

16.3

0.31 (0.20, 0.47)

< 0.001

0.31 (0.20, 0.47)

< 0.001

N/A

N/A

APA aldosterone-producing adenoma, CI confidence interval, EH essential hypertension, NA nonavailable, PA primary aldosteronism

*Multivariate Cox regression model selected covariates from all variables presented in Table 1 by a stepwise procedure

bCompeting risk regression model included age, gender, and propensity score as covariates

As shown in Table 3, patients with PA who received adrenalectomy had an attenuated risk of developing sepsis (adjusted HR 0.14, P = 0.001) compared to matched EH patients analyzed by the multivariate Cox regression model, even after accounting for the competing risk of death (competing hazard ratio (cHR) 0.14, P = 0.001; we used cHR as the hazard ratio after accounting for the competing risk of death). A similar result was also found in septic shock (cHR 0.14, P = 0.005) after accounting for the competing risk of death. Lower risk of mortality was also found in PA patients after adrenalectomy (adjusted HR 0.21, P < 0.001). However, PA patients with MRA had a higher risk of developing sepsis (cHR 1.49, P = 0.004) after taking death as a competing risk than patients with EH. Additional file 4 presents the risks from sepsis and death between PA patients and their EH matches without loss of follow-up patients, for the patients only by target treatments (N = 4874).
Table 3

Comparison of risks from sepsis and death between PA patients and their EH matches, for the whole PA cohort and for the APA subgroup only by target treatments

Outcome

Adrenalectomy

MRA

Crude

Adjusta

Competing riskb

Crude

Adjusteda

Competing riskb

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

 

PA vs EH

PA vs EH

Sepsis

0.12 (0.04,0.39)

< 0.001

0.13 (0.04,0.41)

0.001

0.14 (0.04,0.44)

0.001

1.53 (1.15,2.04)

0.004

1.52 (1.14,2.03)

0.004

1.49 (1.12,1.98)

0.006

Septic shock

0.12 (0.03,0.49)

0.003

0.13 (0.03,0.53)

0.005

0.14 (0.03,0.55)

0.005

1.25 (0.87,1.81)

0.231

1.24 (0.86,1.80)

0.249

1.22 (0.84,1.76)

0.300

All-cause mortality

0.20 (0.12,0.33)

< 0.001

0.21 (0.13,0.36)

< 0.001

N/A

N/A

1.06 (0.89,1.26)

0.526

1.05 (0.88,1.25)

0.606

N/A

N/A

 

APA vs EH

APA vs EH

Sepsis

0.14 (0.04,0.45)

0.001

0.14 (0.04,0.46)

0.001

0.16 (0.05,0.53)

0.003

0.55 (0.23,1.35)

0.193

0.55 (0.22,1.33)

0.184

0.44 (0.18,1.07)

0.071

Septic shock

0.14 (0.03,0.60)

0.008

0.14 (0.03,0.61)

0.009

0.16 (0.04,0.67)

0.012

0.59 (0.20,1.78)

0.352

0.57 (0.19,1.70)

0.314

0.46 (0.15,1.36)

0.160

All-cause mortality

0.25 (0.14,0.43)

< 0.001

0.25 (0.15,0.44)

< 0.001

N/A

N/A

0.42 (0.24,0.76)

0.004

0.40 (0.22,0.72)

0.002

N/A

N/A

APA aldosterone-producing adenoma, CI confidence interval, EH essential hypertension, MRA mineralocorticoid antagonist, NA nonavailable, PA primary aldosteronism

aMultivariate Cox regression model selected covariates from all variables presented in Table 1 by a stepwise procedure. This model constructed adrenalectomy, steroid, and potassium supplement for hypokalemia as time-varying covariates

bCompeting risk regression model included age, gender, and propensity score as covariates

Long-term risks of sepsis and mortality between APA and matched EH patients

A lower sepsis rate was found in the APA cohort than in their matched EH cohort (1.03% vs 3.31%, P = 0.001) after target treatments during a mean follow-up period of 5.56 years (Table 1).

The adjusted HR for developing sepsis among the APA cohort after target treatments, relative to the EH cohort, was 0.29 (P < 0.001) taking into account the competing effects of death (Table 2). Taking into account death as a competing risk, the adjusted HR for developing septic shock between the APA and EH cohorts was 0.30 (P = 0.010). The adjusted HR for developing mortality among the APA cohort, relative to the EH cohort, was 0.31 (P < 0.001) (Table 2).

As shown in Table 3, patients with APA with adrenalectomy had a lower risk of developing sepsis (cHR 0.16, P = 0.003) and mortality (adjusted HR 0.25, P < 0.001) than patients with EH. Inconsistent with the aforementioned result, a lower incidence was also found in developing septic shock (cHR 0.16, P = 0.012) by adjusting death as a competing risk in APA rather than EH patients. However, patients with APA with only MRA treatment did not benefit from a reduced incidence of sepsis (cHR 0.44, P = 0.071) and septic shock (HR 0.46, P = 0.160). Nonetheless, MRA treatment could attenuate the risk of mortality in APA patients (adjusted HR 0.40, P = 0.002).

In the subgroup analysis by forest plot, the benefit of adrenalectomy on decreasing the risk of developing sepsis was also noted in patients with PA/APA compared with matched EH patients (Fig. 2).
Fig. 2
Fig. 2

Risk of sepsis between PA (a) and APA (b) patients with adrenalectomy and their EH controls by participant characteristics. ACEI angiotensin-converting enzyme inhibitor, APA aldosterone-producing adenoma, ARB angiotensin receptor blocker, CI confidence interval, EH essential hypertension, NSAID nonsteroidal antiinflammatory drug, OP operation, PA primary aldosteronism

Furthermore, corresponding cumulative incidence curves that depict the accumulated proportions of incident sepsis showed a significantly lower rate in patients who received adrenalectomy than in patients under MRA treatment and EH patients after adjusting for age, gender, and Charlson morbidity index with death as a competing risk (Fig. 3a, b) (operation (OP) vs MRA, P < 0.001 and OP vs EH, P = 0.002 in PA group; OP vs MRA, p = 0.008 and OP vs EH, P = 0.001 in APA group).
Fig. 3
Fig. 3

Proportional curve (adjusted with age, gender, and Charlson score) for sepsis in patients with adrenalectomy (OP), mineralocorticoid receptor antagonist (MRA) treatment, and essential hypertension (EH) during follow-up period by Cox regression model. Cumulative proportions to sepsis of PA (a) and APA (b) patients after target treatments (adrenalectomy or MRA treatment) and their EH controls by Cox proportional plot, taking mortality as a competing risk. Cox regression: (a) P < 0.001 (OP/MRA) and P = 0.001 (OP/EH); (b) P = 0.030 (OP/MRA) and P = 0.003 (OP/EH)

Discussion

In this population-based cohort study, we demonstrated the treatment benefit of adrenalectomy on attenuating the sepsis incidence among PA patients. However, the effect of MRA treatment on sepsis may differ. In addition, the risk of adrenalectomy-related adrenal insufficiency and subsequent shock during septic status is not significant. In line with the previous findings, our results further indicate that patients with PA/APA could benefit from MRA treatment or adrenalectomy in terms of long-term all-cause mortality.

Immune system dysregulation with hyperaldosteronism

In addition to the regulatory role of the body fluid and electrolyte balance, prolonged exposure to hyperaldosterone causes cardiac and renal damage independent of high blood pressure levels [23, 24]. In light of recent concepts, chronic inflammatory disease could be attributed to sepsis [25, 26], and PA was regarded as a chronic inflammatory disease which may result from immune dysfunction.

Heart failure in patients with PA is attributed to the overproduction of oxidative stress and proinflammatory cytokine augmented by hyperaldosterone [6, 27]; this phenomenon was reported to be promoted by aldosterone and related to dysfunction of innate and adaptive immunity. On the other hand, proinflammatory cytokines could also play an important role. Krysiak and Okopien reported that higher levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 1 beta (IL-1β) from monocytes/macrophages and of interleukin 2 (IL-2), interferon gamma (IFN-γ), and TNF-α from lymphocytes were found in patients with APA than in patients with EH [28].

The possibility of glucocorticoid co-secretion in PA has been demonstrated by Arlt et al. [10], which could be an important reason for the higher sepsis risk in patients with PA. Glucocorticoid could alter and influence the cellular response to infection and the humoral component [29]. These conditions indicate that glucocorticoid excess is associated with immune dysfunction and is responsible for the susceptibility to infections.

Previous studies demonstrated that the role of the renin–angiotensin–aldosterone system according to increasing aldosterone level was noted after endotoxin infusion in an animal model [30]. In addition, Annane et al. [31] revealed that the patients with septic shock who received hydrocortisone plus fludrocortisone for 7 days had better long-term outcome than the placebo group. These studies showed the potential benefit of aldosterone and glucocorticoid in sepsis. However, long-term exposure to a high aldosterone level of PA patients may increase their sepsis risk resulting from chronic inflammation and immune dysfunction.

Long-term outcome after target treatments to aldosteronism

In our study, adrenalectomy gains the benefit of ameliorating sepsis; however, MRA treatment may differ. PA patients exhibited decreased levels of transforming growth factor beta (TGF-β) and TNF-α, compared to normotensive patients; however, MRA treatment could only restore levels of TGF-β [32]. These results may, at least partly, explain the reason for the limited benefit of MRA treatment on decreasing the sepsis risk in patients with PA.

In addition, adrenalectomy might yield a therapeutic effect more rapidly [33], and it takes more than 1 year to ameliorate overhydration [34] and 6 years to observe reductions in left ventricular wall thickness and masses in PA patients after MRA treatment [35].

The benefit of adrenalectomy could also be explained by glucocorticoid co-secretion in PA. In recent studies, adrenalectomy in patients with APA could decrease glucocorticoid secretion, restore osteoporosis, attenuate adverse metabolic risk, and improve the quality of life [10, 22, 36, 37], which are attributed to decreased glucocorticoid levels in addition to mineralocorticoid excess.

Adrenal dysfunction and sepsis/septic shock

Adrenal insufficiency was noted after unilateral adrenalectomy in patients with Cushing syndrome [38]; however, there were few reports about adrenal insufficiency in PA patients after unilateral adrenalectomy. Honda et al. [39] demonstrated that the cortisol level is sustained with an elevated adrenocorticotropic hormone (ACTH) level in APA patients who had status post unilateral adrenalectomy, which has raised the possibility of clinical adrenal insufficiency among them. Activation of the renin–angiotensin–aldosterone system (RAAS) is an important mechanism to preserve volume status and vascular tone [40]. However, high levels of inflammatory cytokines in patients with sepsis will inhibit adrenal cortisol synthesis [41]. Our results identified that APA patients who received unilateral adrenalectomy would not augment the risk of septic shock, as a result of adrenal insufficiency during severe stress.

Adrenalectomy and MRA treatment gains the benefit of long-term all-cause mortality

The long-term different outcome of PA patients treated with adrenalectomy or MRA is still under debate. In our study, APA patients with adrenalectomy and MRA both had lower mortality than EH patients. We have found that adrenalectomy may reduce long-term all-cause mortality among PA patients, while MRA prescription may also help in this regard when its dosage is appropriate [13]. Interestingly, some small-scale studies have shown no difference between surgically and medically treated patients with PA in terms of the incidence of cardiovascular events [33, 42]. Our result raises an important, at least partial, account for the long-term improvement of mortality by sepsis in PA patients out of proportion to cardiovascular event improvement that only benefits substantially from adrenalectomy in the long-term follow-up.

Study limitations

There were several limitations to our study. First, the diagnosis of PA, APA, and EH and the morbidities were identified by ICD-9-CM codes. Even though this study has a large patient size, some degree of misclassification might have affected the identification of patients. Second, as an observational study, there was still the possibility of selection bias and unmeasured confounding factors in our study. The results of our study could only demonstrate the association between aldosterone and sepsis, and it is hard to prove a causal relationship between aldosterone and sepsis and mortality in this study. We still need further investigation to clarify the relation between hyperaldosteronism and immune dysfunction. Third, the NHIRD did not contain information on several factors, including body mass index, nutritional status, and laboratory findings. However, a placebo-controlled randomized clinical trial regarding MRA or adrenalectomy over as many years as in our observational study is not possible nor is it ethically acceptable to conduct; our prospective follow-up study provided a valid alternative [43]. Fourth, this study used population-based health insurance registration data, where the diagnostic results were not ‘controlled’ as ideally as some single or multicenter clinical studies could have easily achieved.

Conclusions

Our study demonstrated that patients with aldosteronism under adrenalectomy could attenuate the incidence of sepsis compared to patients with EH; however, patients receiving long-term MRA treatment may differ. Unilateral adrenalectomy of APA will not augment a risk of adrenal insufficiency under the stress of sepsis. We further found that APA patients under adrenalectomy and MRA treatments both had a lower mortality rate than EH patients. Further investigation is therefore necessary to clarify the effect of aldosterone on immune dysfunction.

Abbreviations

ACTH: 

Adrenocorticotropic hormone

APA: 

Aldosterone-producing adenoma

cHR: 

Competing hazard ratio

CI: 

Confidence interval

EH: 

Essential hypertension

HR: 

Hazard ratio

IFN-γ: 

Interferon gamma

IL-1β: 

Interleukin 1 beta

IL-2: 

Interleukin 2

IL-6: 

Interleukin 6

MR: 

Mineralocorticoid receptor

MRA: 

Mineralocorticoid receptor antagonist

NHRI: 

National Health Research Institutes

OP: 

Operation

PA: 

Primary aldosteronism

RAAS: 

Renin–angiotensin–aldosterone system

TGF-β: 

Transforming growth factor beta

TNF-α: 

Tumor necrosis factor alpha

TNHI: 

Taiwan National Health Insurance

Declarations

Acknowledgements

The study was partly based on data provided by the National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. The interpretation and conclusions shown in this article do not represent those of the National Health Insurance Administration, Ministry of Health and Welfare, National Health Research Institutes, or National Taiwan University Hospital. The authors also express sincere gratitude to all staff of the Taiwan Clinical Trial Consortium (TCTC).

Membership of the Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group: Vin-Cent Wu, MD (NTUH); Chieh-Kai Chan (NTUH Hsin-Chu branch); Jui-Hsiang Lin, MD (Tao-Yuan General Hospital); Wei-Jie Wang, MD, PhD (Tao-Yuan General Hospital); Che-Hsiung Wu, MD, Ya-Hui Hu, Leay Kiaw Er, Chia-Hui Chang, Ya-Li Chang, Yao-Chou Tsai, and Chih-Chin Yu (Taipei Tzu Chi Hospital); Yen-Hung Lin, MD (NTUH); Yi-Luwn Ho, MD, PhD (NTUH); Hung-Wei Chang, MD, PhD (Far Eastern Hospital); Lian-Yu Lin MD, PhD (NTUH); Fu-Chang Hu, MS, ScD (Harvard Statistics); Chin-Chen Chang and Kao-Lang Liu, MD (NTUH); Shuo-Meng Wang, MD (NTUH); Kuo-How Huang, MD (NTUH); Shih-Chieh Jeff Chueh, MD, PhD (Cleveland Clinic); Shih-Cheng Liao, MD (NTUH); Ching-Chu Lu and Ruoh-Fang Yen, MD, PhD (NTUH); and Kwan-Dun Wu, MD, PhD (NTUH, Director of Coordinating Center).

Funding

This study was supported by Taiwan National Science Council (101–2314-B-002-085-MY3, 102–2314-B-002-140-MY2, 104–2314-B-002-125-MY3, 106–2314-B-002-166-MY3,107–2314-B-002-026-MY3), National Health Research Institutes (PH-102-SP-09), National Taiwan University Hospital (106-FTN20, 106-P02, UN106–014, 106-S3582, 105-P05, VN105–04, 105-S3061, 107-S3809, 107-T02), and Ministry of Science and Technology (MOST) of the Republic of China (Taiwan) (grant number MOST 106–2321-B-182-002).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

V-C Wu and K-D Wu originated the concept for this study. C-K Chan, Y-H Hu, Likwang Chen and T-S Lai participated in collecting data and conducted the analyses. All authors planned the study design and contributed to the interpretation of the data. C-K Chan drafted the manuscript and all authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu branch, Hsin Chu, Taiwan
(2)
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
(3)
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan
(4)
Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan
(5)
Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan
(6)
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
(7)
TAIPAI, Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group, Taipei, Taiwan
(8)
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

References

  1. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.View ArticleGoogle Scholar
  2. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921–6.View ArticleGoogle Scholar
  3. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16(3):104–7.View ArticleGoogle Scholar
  4. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66(1):1–9.View ArticleGoogle Scholar
  5. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens. 2011;29(9):1684–92.View ArticleGoogle Scholar
  6. Kotlyar E, Vita JA, Winter MR, Awtry EH, Siwik DA, Keaney JF Jr, Sawyer DB, Cupples LA, Colucci WS, Sam F. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail. 2006;12(2):122–7.View ArticleGoogle Scholar
  7. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 2002;161(5):1773–81.View ArticleGoogle Scholar
  8. Grafte-Faure S, Leveque C, Vasse M, Soria C, Norris V, Vannier JP. Effects of glucocorticoids and mineralocorticoids on proliferation and maturation of human peripheral blood stem cells. Am J Hematol. 1999;62(2):65–73.View ArticleGoogle Scholar
  9. Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiyama H, Sasano H, Hirata Y. Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome. Endocr J. 2011;58(7):543–51.View ArticleGoogle Scholar
  10. Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, Feuchtinger A, Chortis V, Gilligan LC, Ludwig P, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI insight. 2017;2(8). [Epub ahead of print]Google Scholar
  11. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–29.View ArticleGoogle Scholar
  12. Wu VC, Hu YH, Wu CH, Kao CC, Wang CY, Yang WS, Lee HH, Chang YS, Lin YH, Wang SM, et al. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan. J Clin Epidemiol. 2014;67(10):1139–49.View ArticleGoogle Scholar
  13. Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD. Long term outcome of aldosteronism after target treatments. Sci Rep. 2016;6:32103.View ArticleGoogle Scholar
  14. Wu VC, Hu YH, Er LK, Yen RF, Chang CH, Chang YL, Lu CC, Chang CC, Lin JH, Lin YH, et al. Case detection and diagnosis of primary aldosteronism—the consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc. 2017;116(12):993–1005.View ArticleGoogle Scholar
  15. Chiang CE, Wang TD, Ueng KC, Lin TH, Yeh HI, Chen CY, Wu YJ, Tsai WC, Chao TH, Chen CH, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc. 2015;78(1):1–47.View ArticleGoogle Scholar
  16. Lai TS, Wang CY, Pan SC, Huang TM, Lin MC, Lai CF, Wu CH, Wu VC, Chien KL. Risk of developing severe sepsis after acute kidney injury: a population-based cohort study. Crit Care. 2013;17(5):R231.View ArticleGoogle Scholar
  17. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan from 1997 through 2006. Chest. 2010;138(2):298–304.View ArticleGoogle Scholar
  18. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.View ArticleGoogle Scholar
  19. Black N, Payne M. Directory of clinical databases: improving and promoting their use. Qual Saf Health Care. 2003;12(5):348–52.View ArticleGoogle Scholar
  20. Wu VC, Wu CH, Huang TM, Wang CY, Lai CF, Shiao CC, Chang CH, Lin SL, Chen YY, Chen YM, et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol. 2014;25(3):595–605.View ArticleGoogle Scholar
  21. Wu VC, Wu PC, Wu CH, Huang TM, Chang CH, Tsai PR, Ko WJ, Chen L, Wang CY, Chu TS, et al. The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc. 2014;3(4):e000933.View ArticleGoogle Scholar
  22. Wu VC, Chang CH, Wang CY, Lin YH, Kao TW, Lin PC, Chu TS, Chang YS, Chen L, Wu KD, et al. Risk of fracture in primary aldosteronism: a population-based cohort study. J Bone Miner Res. 2017;32(4):743–52.View ArticleGoogle Scholar
  23. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clinical Science (London, England : 1979). 2007;113(6):267–78.View ArticleGoogle Scholar
  24. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98(4):1063–8.View ArticleGoogle Scholar
  25. Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial. 2011;24(1):56–64.View ArticleGoogle Scholar
  26. Muniz-Junqueira MI, Braga Lopes C, Magalhaes CA, Schleicher CC, Veiga JP. Acute and chronic influence of hemodialysis according to the membrane used on phagocytic function of neutrophils and monocytes and pro-inflammatory cytokines production in chronic renal failure patients. Life Sci. 2005;77(25):3141–55.View ArticleGoogle Scholar
  27. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, Fukuoka T, Higaki J. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens. 2006;19(3):293–7.View ArticleGoogle Scholar
  28. Krysiak R, Okopien B. The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma. Hypertens Res. 2012;35(1):123–5.View ArticleGoogle Scholar
  29. Fareau GG, Vassilopoulou-Sellin R. Hypercortisolemia and infection. Infect Dis Clin N Am. 2007;21(3):639–57 viii.View ArticleGoogle Scholar
  30. White FN, Gold EM, Vaughn DL. Renin-aldosterone system in endotoxin shock in the dog. Am J Phys. 1967;212(5):1195–8.Google Scholar
  31. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–18.View ArticleGoogle Scholar
  32. Carvajal CA, Herrada AA, Castillo CR, Contreras FJ, Stehr CB, Mosso LM, Kalergis AM, Fardella CE. Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J Endocrinol Investig. 2009;32(9):759–65.View ArticleGoogle Scholar
  33. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80–5.View ArticleGoogle Scholar
  34. Wu CH, Yang YW, Hung SC, Tsai YC, Hu YH, Lin YH, Chu TS, Wu KD, Wu VC. Effect of treatment on body fluid in patients with unilateral aldosterone producing adenoma: adrenalectomy versus spironolactone. Sci Rep. 2015;5:15297.View ArticleGoogle Scholar
  35. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50(5):911–8.View ArticleGoogle Scholar
  36. Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS, Group TS. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens. 2017;35(8):1698–708.View ArticleGoogle Scholar
  37. Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95(3):1360–4.View ArticleGoogle Scholar
  38. Shen WT, Lee J, Kebebew E, Clark OH, Duh Q. Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg. 2006;141(8):771–6.View ArticleGoogle Scholar
  39. Honda K, Sone M, Tamura N, Sonoyama T, Taura D, Kojima K, Fukuda Y, Tanaka S, Yasuno S, Fujii T, et al. Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism. J Hypertens. 2013;31(10):2010–7.View ArticleGoogle Scholar
  40. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004;351(2):159–69.View ArticleGoogle Scholar
  41. Catalano RD, Parameswaran V, Ramachandran J, Trunkey DD. Mechanisms of adrenocortical depression during Escherichia coli shock. Arch Surg (Chicago Ill : 1960). 1984;119(2):145–50.View ArticleGoogle Scholar
  42. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62–9.View ArticleGoogle Scholar
  43. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement